SG Americas Securities LLC Has $780,000 Stake in Nektar Therapeutics (NKTR)

SG Americas Securities LLC grew its holdings in shares of Nektar Therapeutics (NASDAQ:NKTR) by 88.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 32,484 shares of the biopharmaceutical company’s stock after buying an additional 15,269 shares during the quarter. SG Americas Securities LLC’s holdings in Nektar Therapeutics were worth $780,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of the company. LS Investment Advisors LLC grew its holdings in shares of Nektar Therapeutics by 8.8% during the second quarter. LS Investment Advisors LLC now owns 6,594 shares of the biopharmaceutical company’s stock valued at $129,000 after buying an additional 535 shares during the last quarter. World Asset Management Inc grew its holdings in shares of Nektar Therapeutics by 5.6% during the second quarter. World Asset Management Inc now owns 10,167 shares of the biopharmaceutical company’s stock valued at $199,000 after buying an additional 539 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Nektar Therapeutics by 14.1% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,603 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 692 shares during the last quarter. Arizona State Retirement System grew its holdings in shares of Nektar Therapeutics by 1.0% during the second quarter. Arizona State Retirement System now owns 80,945 shares of the biopharmaceutical company’s stock valued at $1,582,000 after buying an additional 800 shares during the last quarter. Finally, Ameritas Investment Partners Inc. grew its holdings in shares of Nektar Therapeutics by 7.7% during the second quarter. Ameritas Investment Partners Inc. now owns 13,011 shares of the biopharmaceutical company’s stock valued at $254,000 after buying an additional 929 shares during the last quarter. Hedge funds and other institutional investors own 96.04% of the company’s stock.

Nektar Therapeutics (NASDAQ:NKTR) opened at $51.92 on Wednesday. Nektar Therapeutics has a twelve month low of $11.41 and a twelve month high of $55.42. The company has a debt-to-equity ratio of 2.91, a current ratio of 4.14 and a quick ratio of 3.99.

Nektar Therapeutics (NASDAQ:NKTR) last released its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported $0.37 earnings per share for the quarter, topping the consensus estimate of $0.21 by $0.16. Nektar Therapeutics had a negative net margin of 42.08% and a negative return on equity of 190.68%. The business had revenue of $152.90 million for the quarter, compared to analysts’ expectations of $126.50 million. During the same period in the previous year, the company earned ($0.32) earnings per share. The firm’s revenue for the quarter was up 321.2% compared to the same quarter last year. equities research analysts forecast that Nektar Therapeutics will post -0.75 earnings per share for the current year.

A number of brokerages have recently issued reports on NKTR. Jefferies Group reiterated a “buy” rating and set a $23.00 price objective on shares of Nektar Therapeutics in a report on Friday, August 18th. BidaskClub upgraded shares of Nektar Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, August 17th. Mizuho reiterated a “buy” rating and set a $45.00 price objective (up from $30.00) on shares of Nektar Therapeutics in a report on Wednesday, November 8th. Zacks Investment Research cut shares of Nektar Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, August 11th. Finally, Canaccord Genuity boosted their price target on shares of Nektar Therapeutics from $35.00 to $50.00 and gave the stock a “buy” rating in a report on Monday, November 13th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and twelve have assigned a buy rating to the company. Nektar Therapeutics has a consensus rating of “Buy” and a consensus price target of $35.58.

In other Nektar Therapeutics news, SVP Ivan P. Gergel sold 100,000 shares of the business’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $24.14, for a total value of $2,414,000.00. Following the transaction, the senior vice president now directly owns 84,871 shares in the company, valued at $2,048,785.94. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, COO John Nicholson sold 15,910 shares of the business’s stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $37.78, for a total transaction of $601,079.80. Following the completion of the transaction, the chief operating officer now owns 249,066 shares in the company, valued at $9,409,713.48. The disclosure for this sale can be found here. Over the last quarter, insiders sold 858,094 shares of company stock worth $22,868,634. Corporate insiders own 5.44% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This news story was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another website, it was illegally copied and republished in violation of U.S. & international copyright & trademark laws. The original version of this news story can be read at https://www.dispatchtribunal.com/2017/12/06/sg-americas-securities-llc-has-780000-stake-in-nektar-therapeutics-nktr.html.

About Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Want to see what other hedge funds are holding NKTR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nektar Therapeutics (NASDAQ:NKTR).

Institutional Ownership by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply